Biotechnology
Biopharmaceutical
Health

Omeros

$17.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.12 (-5.90%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Omeros and other stocks, options, ETFs, and crypto commission-free!

About

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. Read More It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Employees
236
Headquarters
Seattle, Washington
Founded
1994
Market Cap
875.54M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
682.09K
High Today
$19.25
Low Today
$17.80
Open Price
$19.07
Volume
214.36K
52 Week High
$27.00
52 Week Low
$10.30

Collections

Biotechnology
Biopharmaceutical
Health
Therapy
Pharmaceutical
Technology
US
North America

News

Yahoo FinanceMay 15

Omeros to Present at the UBS Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at 8:00 a.m. EDT. The presentation will be webcast. The live and archived webcasts can be accessed on the investor relations page of company’s website at www.omeros.com. Scroll to continue with content Ad About Omeros Corporation Ome...

37
Yahoo FinanceMay 9

Omeros Reports Q1 Loss, Lags Revenue Estimates

Omeros (OMER) delivered earnings and revenue surprises of -11.76% and -4.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

46
Yahoo FinanceMay 9

Omeros Corporation Reports First Quarter 2019 Financial Results

SEATTLE--(BUSINESS WIRE)-- – Conference Call Today at 4:30 p.m. ET – Omeros Corporation (OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for...

23

Earnings

-$0.81
-$0.59
-$0.38
-$0.16
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.